About AbRegen

AbRegen is a development company that specialises in antibody based therapeutics to treat epithelial lesions of skin and other organs.

AbRegen is a preclinical stage biotechnology company that specialises in the development of antibody-based therapeutics for tissue repair applications.

AbRegen owns intellectual property related to the modulation of Flightless I, a key regulator of cell growth and migration. The technology has application to disorders of cellular movement and proliferation, including non-healing chronic wounds, burn injury, cancer and fragile skin disorders.

AbRegen’s current development program is focussed on an antibody-based therapy for epidermolysis bullosa. A topical anti-flightless I treatment holds significant potential to promote wound repair, decrease skin fragility and inhibit growth of the aggressive squamous cell carcinomas that affect patients with severe forms of this genetic disorder.

Therapeutic antibodies for regenerative medicine.

AbRegen is a preclinical stage biotechnology company that specialises in the development of antibody-based therapeutics for tissue repair applications.